| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥3075.2B | ¥3142.3B | -2.1% |
| Operating Income | ¥182.7B | ¥101.8B | +79.6% |
| Ordinary Income | ¥158.4B | ¥55.3B | +186.2% |
| Net Income | ¥95.2B | ¥34.6B | +174.7% |
| ROE | 4.0% | 1.5% | - |
FY2025 Q3 cumulative results showed revenue of 307.5B yen (YoY -2.1%), operating income of 18.3B yen (YoY +79.6%), ordinary income of 15.8B yen (YoY +186.2%), and net income attributable to owners of 9.5B yen (YoY +174.7%). Despite the slight revenue decline, profitability improved substantially with operating margin expanding to 5.9% from 3.2% in the prior year period. This marks a significant turnaround in earnings quality, though the company continues to face challenges in capital efficiency with ROE remaining at 3.2% and ROIC at 3.9%. The full-year forecast targets revenue of 430.0B yen, operating income of 24.0B yen, and net income of 8.5B yen.
Revenue declined 2.1% YoY to 307.5B yen, primarily driven by softness in the Environment and Functional Materials segment (77.9B yen, -6.8% YoY) and Functional Fiber and Trading segment (66.2B yen, -7.1% YoY), partially offset by growth in the Film segment (130.0B yen, +4.1% YoY). The Real Estate segment showed modest growth to 3.4B yen (+7.4% YoY), while the Life Science segment contracted slightly to 24.8B yen (-3.6% YoY). Despite the top-line pressure, operating income surged 79.6% YoY to 18.3B yen, reflecting improved gross profit margins and effective cost management. Gross profit reached 76.6B yen, while selling, general and administrative expenses were controlled at 58.3B yen. The profit improvement was broad-based across segments, with the Film segment achieving operating income of 12.9B yen (up from 3.8B yen YoY), marking a significant turnaround. The Environment and Functional Materials segment maintained profitability at 5.4B yen despite revenue headwinds. The Life Science segment incurred an operating loss of 0.3B yen, deteriorating from a profit of 1.5B yen in the prior year. Ordinary income expanded more substantially than operating income, increasing 186.2% YoY to 15.8B yen, benefiting from reduced non-operating expenses. The gap between operating income (18.3B yen) and ordinary income (15.8B yen) of 2.5B yen reflects net non-operating losses, primarily interest expenses of 2.1B yen. Net income attributable to owners reached 9.5B yen, up from 3.5B yen YoY, despite special losses of 4.1B yen (including impairment losses of 0.2B yen) partially offset by special gains of 1.6B yen. This represents a revenue down, profit up pattern, indicating successful margin expansion initiatives despite challenging demand conditions.
The Film segment is the core business, generating 130.0B yen in revenue (42.3% of total) and 12.9B yen in operating income, representing a dramatic profitability recovery from 3.8B yen in the prior year. This segment achieved an operating margin of approximately 9.9%, substantially higher than the company average. The Environment and Functional Materials segment contributed 77.9B yen in revenue (25.3% of total) with operating income of 5.4B yen, maintaining a healthy margin despite revenue contraction. The Life Science segment, at 24.8B yen in revenue (8.1% of total), turned to an operating loss of 0.3B yen from a profit of 1.5B yen YoY, indicating significant profitability challenges in this division. The Functional Fiber and Trading segment generated 66.2B yen in revenue (21.5% of total) with modest operating income of 0.6B yen, improving from 0.1B yen YoY but maintaining a thin margin of approximately 0.9%. The Real Estate segment, though smaller at 3.4B yen in revenue (1.1% of total), delivered stable operating income of 1.5B yen with a strong margin of approximately 45.3%. The Other category contributed 5.2B yen in revenue with operating income of 0.5B yen. Segment margin dispersion is material, with Real Estate and Film demonstrating superior profitability while Life Science faces restructuring needs.
[Profitability] Operating margin improved to 5.9% from 3.2% YoY, reflecting enhanced pricing power and cost management. Net profit margin reached 3.1%, up from 1.1% in the prior year. ROE stands at 3.2%, calculated from net profit margin of 2.5% (on annualized basis), total asset turnover of 0.50, and financial leverage of 2.56. ROIC improved to 3.9% but remains below the company's cost of capital. [Cash Quality] Cash and deposits totaled 24.6B yen, providing coverage of 0.49 times short-term debt of 50.5B yen, indicating tight liquidity conditions. Working capital of 109.3B yen represents a significant capital commitment, with contract assets standing at 1.1B yen. [Investment Efficiency] Total asset turnover is 0.50, below the manufacturing industry median of 0.58. Inventory turnover of 107 days and receivables turnover of 95 days suggest room for working capital efficiency improvements. Tangible fixed assets total 301.3B yen with construction in progress of 49.4B yen, indicating ongoing capital investments. [Financial Health] Equity ratio stands at 39.1%, below the industry median of 63.8%, with total equity of 240.9B yen against total assets of 616.8B yen. Current ratio of 171.2% and quick ratio of 127.1% indicate adequate short-term liquidity coverage, though cash-to-short-term-debt ratio warrants monitoring. Debt-to-equity ratio is 1.56, with long-term borrowings of 112.2B yen and interest expense of 2.1B yen, resulting in an interest coverage ratio of 8.6 times.
Cash and deposits decreased from 61.8B yen in the prior year to 24.6B yen at the current period-end, representing a significant decline of 37.2B yen. This cash reduction occurred despite the substantial improvement in operating profitability, suggesting significant cash absorption from working capital and investing activities. The working capital position increased to 109.3B yen, with inventory turnover of 107 days and receivables turnover of 95 days indicating extended cash conversion cycles. Accounts payable turnover of 62 days provides some natural financing offset. The presence of construction in progress of 49.4B yen suggests ongoing capital expenditure programs absorbing cash. Short-term borrowings of 50.5B yen and long-term debt of 112.2B yen indicate reliance on debt financing, with interest payments of 2.1B yen representing a recurring cash outflow. The cash-to-short-term-debt coverage ratio of 0.49 times signals liquidity stress, as current cash holdings are insufficient to cover near-term debt obligations without operational cash generation or refinancing. The substantial decline in cash position despite profit improvement highlights the importance of working capital management and suggests that earnings quality may be constrained by non-cash accruals or capital intensity.
Ordinary income of 15.8B yen compared to operating income of 18.3B yen reflects a non-operating net loss of approximately 2.5B yen. This primarily comprises interest expenses of 2.1B yen, indicating the cost of debt financing on the company's leveraged balance sheet. Non-operating expenses represent approximately 0.8% of revenue, a manageable proportion that reflects the company's moderate leverage profile. The gap between net income attributable to owners of 9.5B yen and ordinary income of 15.8B yen of approximately 6.3B yen is explained by income taxes and the differential between pre-tax income of 11.7B yen and after-tax results. Special items had a net negative impact with special losses of 4.1B yen exceeding special gains of 1.6B yen by 2.5B yen, though the scale is relatively modest at 0.8% of revenue. The substantial divergence between reported profit growth (174.7% for net income) and cash position decline raises questions about earnings quality from a cash generation perspective. The extended working capital cycle with 107-day inventory turnover and 95-day receivables turnover suggests that a significant portion of reported earnings may be tied up in non-cash working capital, indicating moderate earnings quality that warrants monitoring of cash conversion improvements.
The company maintains its full-year forecast of revenue at 430.0B yen, operating income at 24.0B yen, ordinary income at 19.5B yen, and net income attributable to owners at 8.5B yen. Against the nine-month cumulative results, revenue progress stands at 71.5% of the full-year target, operating income at 76.1%, ordinary income at 81.2%, and net income at 112.0%. The revenue progress rate of 71.5% is moderately below the standard Q3 benchmark of 75.0%, suggesting potential fourth-quarter acceleration is needed or conservative full-year guidance. Operating income progress at 76.1% exceeds the standard pace, indicating strong profitability momentum. Notably, net income has already surpassed the full-year forecast at 112.0% of target, suggesting either conservative guidance or potential fourth-quarter headwinds that management anticipates. The company projects full-year operating margin improvement to 5.6% from 3.2% in the prior full year, representing a 2.4 percentage point expansion. Year-over-year guidance changes show expected revenue growth of 1.9%, operating income growth of 44.1%, and ordinary income growth of 84.1%, confirming the profit recovery trajectory while acknowledging modest top-line headwinds.
The company plans a year-end dividend of 40 yen per share with no interim dividend, maintaining the same level as the prior year. Based on full-year forecast EPS of 96.36 yen, the dividend payout ratio is approximately 41.5%, which falls within a reasonable sustainable range. Using the nine-month actual net income of 9.5B yen and estimated share count, the dividend commitment appears manageable. However, given the significant decline in cash position from 61.8B yen to 24.6B yen during the nine-month period and the cash-to-short-term-debt ratio of 0.49 times indicating liquidity constraints, the sustainability of dividend payments warrants monitoring pending improvements in cash conversion from operations and working capital efficiency. No share buyback program has been disclosed for this period, so the total return ratio equals the payout ratio of approximately 41.5%. The dividend policy appears calibrated to balance shareholder returns with the need to preserve cash for working capital and debt service obligations.
First, liquidity risk is elevated with cash holdings of 24.6B yen providing only 0.49 times coverage of short-term debt of 50.5B yen, and cash declining 37.2B yen YoY despite strong profit growth, indicating potential strain in funding operations and debt refinancing needs. Second, working capital efficiency deterioration poses operational risk, with inventory turnover at 107 days and receivables at 95 days extending the cash conversion cycle to over 140 days on a net basis, tying up significant capital and constraining free cash flow generation. Third, segment profit volatility, particularly the Life Science segment swinging from 1.5B yen profit to 0.3B yen loss YoY, creates earnings sustainability concerns and may require restructuring investments or strategic repositioning, potentially pressuring consolidated profitability if not addressed.
[Industry Position] (Reference - Proprietary Analysis) The company's profitability metrics show improvement but remain below manufacturing industry standards. Operating margin of 5.9% is substantially below the industry median of 8.7%, ranking in the lower quartile (industry IQR: 5.1%-12.6%). Net profit margin of 3.1% also trails the industry median of 6.4% (IQR: 3.3%-9.3%), indicating room for further efficiency gains. ROE of 3.2% significantly underperforms the industry median of 5.2% (IQR: 3.0%-8.3%), reflecting suboptimal capital efficiency. The equity ratio of 39.1% is materially below the industry median of 63.8% (IQR: 49.4%-74.5%), placing the company in a more leveraged position with financial leverage of 2.56 versus industry median of 1.53. Asset turnover of 0.50 lags the industry median of 0.58 (IQR: 0.41-0.66), confirming capital efficiency challenges. Working capital metrics reveal specific pressure points: receivables turnover of 95 days exceeds the industry median of 83 days, and total working capital cycle of approximately 140 days net exceeds the industry median of 108 days. The revenue decline of 2.1% contrasts with industry median growth of 2.8% (IQR: -1.7% to 8.1%), positioning the company below median on growth. Current ratio of 171.2% (1.71x) is below the industry median of 2.83x (IQR: 2.11x-3.80x), though still adequate. These benchmarks indicate the company operates with below-average profitability, higher leverage, and tighter liquidity than typical manufacturing peers, though recent margin improvements suggest a positive trajectory.
The earnings data reveals a significant profitability inflection with operating income expanding 79.6% YoY despite revenue contraction of 2.1%, driven primarily by the Film segment's dramatic turnaround to 12.9B yen operating income and successful margin expansion across most divisions. However, this profit improvement has not translated to cash generation, as evidenced by the 37.2B yen decline in cash holdings to 24.6B yen, creating a disconnect between reported earnings and liquidity that stems from extended working capital cycles with 107-day inventory turnover and 95-day receivables collection periods. The capital structure shows elevated financial risk with equity ratio of 39.1% below the manufacturing industry median of 63.8%, debt-to-equity ratio of 1.56, and cash coverage of short-term debt at only 0.49 times, positioning the company as more leveraged and liquidity-constrained than industry peers. The full-year guidance implies fourth-quarter revenue acceleration may be needed while net income has already exceeded annual targets at 112.0% progress, suggesting either conservative forecasting or anticipated one-time items, and the maintained dividend of 40 yen per share appears manageable at 41.5% payout ratio though sustainability depends on improved cash conversion given current liquidity constraints.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.